Open AccessA Randomized Phase IIa Trial with Temsirolimus versus Sunitinib in Advanced Non-Clear Cell Renal Cell Carcinoma: An Intergroup Study of the CESAR Central European Society for Anticancer Drug Research-EWIV and the Interdisciplinary Working Group on Renal Cell Cancer (IAGN) of the German Cancer Society
Author(s) -
Lothar Bergmann,
Viktor Grünwald,
Luise Maute,
Marc-Oliver Grimm,
Steffen Weikert,
Jan Schleicher,
Theodor Klotz,
Jochen Greiner,
Anne Flörcken,
Arndt Hartmann,
Thomas Gauler
Publication year - 2020
Publication title -
oncology research and treatment
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.553
H-Index - 48
eISSN - 2296-5262
pISSN - 2296-5270
DOI - 10.1159/000508450
Subject(s) - temsirolimus , sunitinib , renal cell carcinoma , medicine , oncology , drug , pharmacology , discovery and development of mtor inhibitors , chemistry , pi3k/akt/mtor pathway , apoptosis , biochemistry
Non-clear cell renal cell cancers (nccRCC) are rare entities, and the optimal therapy in metastatic disease has still to be defined.